Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
about
State-of-the-art human gene therapy: part I. Gene delivery technologiesCRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent InfectionsGenome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transductionCNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector.The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction.Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.
P2860
Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@en
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@nl
type
label
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@en
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@nl
prefLabel
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@en
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@nl
P2860
P356
P1433
P1476
Birth of a new therapeutic pla ...... very to licensed gene therapy.
@en
P2093
Terence R Flotte
P2860
P304
P356
10.1038/MT.2013.226
P577
2013-11-01T00:00:00Z